Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA.

Harrold, Leslie R; Connolly, Sean E; Wittstock, Keith; Zhuo, Joe; Kelly, Sheila; Lehman, Thomas; Shan, Ying; Rebello, Sabrina; Guo, Lin; Khaychuk, Vadim

Harrold, Leslie R; Connolly, Sean E; Wittstock, Keith; Zhuo, Joe; Kelly, Sheila; Lehman, Thomas; Shan, Ying; Rebello, Sabrina; Guo, Lin; Khaychuk, Vadim.

Afiliação

Harrold LR; CorEvitas, LLC, Waltham, MA, USA. lharrold@corevitas.com.
Connolly SE; University of Massachusetts Medical School, Worcester, MA, USA. lharrold@corevitas.com.
Wittstock K; Bristol Myers Squibb, Princeton, NJ, USA.
Zhuo J; US Immunology, Bristol Myers Squibb, Princeton, NJ, USA.
Kelly S; Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA.
Lehman T; Bristol Myers Squibb, Princeton, NJ, USA.
Shan Y; Bristol Myers Squibb, Princeton, NJ, USA.
Rebello S; Department of Biostatistics, CorEvitas, LLC, Waltham, MA, USA.
Guo L; CorEvitas, LLC, Waltham, MA, USA.
Khaychuk V; Department of Biostatistics, CorEvitas, LLC, Waltham, MA, USA.

Rheumatol Ther ; 9(2): 465-480, 2022 Apr.

Article em En | MEDLINE | ID: mdl-34940957

Palavras-chave

Anti-cyclic citrullinated antibodies; Biological therapy; Disease-modifying antirheumatic drugs; Outcome assessment; Rheumatoid arthritis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies Idioma: En Revista: Rheumatol Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google